Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22301802 | 0.90 | HRH3 (0.35) | CYP1A2CYP2D6ALOX15HRH3GNAO1 | |
| SCHEMBL22520648 | 0.86 | HRH3 (0.44) | HRH3GNAO1SMN1; SMN2HSD11B1 | |
| SCHEMBL25090036 | 0.85 | TSHR (0.37) | CYP1A2CYP2D6ALOX15HRH3GNAO1 | |
| SCHEMBL22520759 | 0.85 | CYP1A2 (0.33) | CYP1A2CYP2D6ALOX15HRH3 | |
| SCHEMBL22306420 | 0.82 | TSHR (0.36) | CYP1A2CYP2D6ALOX15GNAO1TSHR | |
| SCHEMBL7908231 | 0.82 | CYP1A2 (0.46) | CYP1A2CYP2D6HRH3GNAO1SMN1; SMN2 | |
| SCHEMBL24475309 | 0.81 | ACHE (0.42) | HRH3SMN1; SMN2TSHREPHX1SIGMAR1 | |
| SCHEMBL26521119 | 0.81 | CARM1 (0.47) | HRH3GNAO1SMN1; SMN2HSD11B1SIGMAR1 | |
| SCHEMBL13804415 | 0.81 | CYP1A2 (0.48) | CYP1A2HRH3GNAO1SMN1; SMN2HSD11B1 | |
| SCHEMBL13061302 | 0.81 | GNAO1 (0.42) | HRH3GNAO1SMN1; SMN2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA UK LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ESR1, GPER1, ESRRG | CYP1A2 467/4885CYP2D6 304/4885ALOX15 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.